Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 797-804

  Zueva, Elina ^a,b   Rubio, Laila Illán ^a,b   Ducongé, Frédéric ^a,b   Tavitian, Bertrand ^a,b  

^a DIF   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

aptamer; metastasis; migration; SELEX

Indexed keywords

APTAMER; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; APTAMERS, NUCLEOTIDE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL LINE, TRANSFORMED; CELL MOVEMENT; CRICETINAE; EMBRYO, MAMMALIAN; FEMALE; FIBROBLASTS; HUMANS; MESOCRICETUS; MICE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PHOSPHORYLATION; SELEX APTAMER TECHNIQUE; WOUND HEALING;

EID: 78649937056     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25401     Document Type: Article

References (37)

1. Tuerk C, Gold L,. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249: 505-10.
2. Ellington AD, Szostak JW,. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346: 818-22.
3. Hermann T, Patel DJ,. Adaptive recognition by nucleic acid aptamers. Science 2000; 287: 820-5.
4. Nimjee SM, Rusconi CP, Sullenger BA,. Aptamers: an emerging class of therapeutics. Annu Rev Med 2005; 56: 555-83.
5. Shamah SM, Healy JM, Cload ST,. Complex target SELEX. Acc Chem Res 2008; 41: 130-8.
6. Blank M, Weinschenk T, Priemer M, Schluesener H,. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001; 276: 16464-8.
7. Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y, Cardona D, Witek RP, Liu C, Tan W,. Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 2008; 80: 721-8.
8. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W,. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006; 103: 11838-43.
9. Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P, Chen HW, Li Y, Tan W,. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 2007; 79: 4900-7.
10. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V, Libri D,. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLo S Biol 2005; 3: e123.
11. Deichman GI, Kashleva HA, Kluchareva TE, Matveeva VA,. Clustering of discrete cell properties essential for tumorigenicity and metastasis. II. Studies of Syrian hamster embryo fibroblasts transformed by Rous sarcoma virus. Int J Cancer 1989; 44: 908-10.
12. Deichman GI, Gurova KV, Dyakova NA,. Accumulation in "normal" lungs of live tumorigenic cells during sub-cutaneous growth of weakly and highly metastasizing tumors and their in vitro sensitivity to growth regulation by normal fibroblasts. Int J Cancer 1994; 59: 530-7.
13. Bartel DP, Szostak JW,. Isolation of new ribozymes from a large pool of random sequences [see comment]. Science 1993; 261: 1411-8.
14. Tatosyan A, Yatsula B, Shtutman M, Moinova E, Kaverina I, Musatkina E, Leskov K, Mizenina O, Zueva E, Calothy G, Dezelee P,. Two novel variants of the v-src oncogene isolated from low and high metastatic RSV-transformed hamster cells. Virology 1996; 216: 347-56.
15. Tavitian B, Haberkorn U,. Darwinian molecular imaging. Eur J Nucl Med Mol Imaging 2009; 36: 1475-82.
16. Que-Gewirth NS, Sullenger BA,. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283-91.
17. Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng YS, Shima DT, Pardi A, Jucker F,. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 2005; 102: 18902-7.
18. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC,. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 2009; 17: 153-61.
19. Pestourie C, Cerchia L, Gombert K, Aissouni Y, Boulay J, De Franciscis V, Libri D, Tavitian B, Duconge F,. Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides 2006; 16: 323-35.
20. Chauveau F, Aissouni Y, Hamm J, Boutin H, Libri D, Duconge F, Tavitian B,. Binding of an aptamer to the N-terminal fragment of VCAM-1. Bioorg Med Chem Lett 2007; 17: 6119-22.
21. Pestourie C, Tavitian B, Duconge F,. Aptamers against extracellular targets for in vivo applications. Biochimie 2005; 87: 921-30.
22. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG,. Tumor targeting by an aptamer. J Nucl Med 2006; 47: 668-78.
23. Wolf K, Friedl P,. Molecular mechanisms of cancer cell invasion and plasticity. Br J Dermatol 2006; 154 (Suppl 1): 11-5.
24. Xiao Z, Shangguan D, Cao Z, Fang X, Tan W,. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 2008; 14: 1769-75.
25. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R,. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004; 64: 7668-72.
26. Mitra SK, Hanson DA, Schlaepfer DD,. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005; 6: 56-68.
27. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R,. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 2007; 67: 4278-86.
28. Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, Rhys-Evans P, P Oc, Eccles S,. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007; 67: 7907-16.
29. Selli C, Amorosi A, Vona G, Sestini R, Travaglini F, Bartoletti R, Orlando C,. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive PCR in collecting duct carcinoma of the kidney. J Urol 1997; 158: 245-7.
30. Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S,. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. Jpn J Clin Oncol 1997; 27: 371-7.
31. Pegram MD, Pauletti G, Slamon DJ,. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998; 52: 65-77.
32. Brandt BH, Roetger A, Dittmar T, Nikolai G, Seeling M, Merschjann A, Nofer JR, Dehmer-Moller G, Junker R, Assmann G, Zaenker KS,. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 1999; 13: 1939-49.
33. Sawyer TK,. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Exp Opin Investig Drugs 2004; 13: 1-19.
34. Tucker GC,. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003; 4: 722-31.
35. Zucker S, Cao J, Chen WT,. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-50.
36. Coussens LM, Fingleton B, Matrisian LM,. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
37. Friedl P, Wolf K,. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.